Wo 2009 alpelisib novartis patent?

When does the alpelisib (Piqray) patent expire in 2009?

Novartis developed alpelisib (Piqray). The patent timeline depends on the specific “WO” patent family and country coverage; patents are tied to application/publication dates and then expire based on filing/term rules, plus any patent-term adjustments or extensions.

To find the exact “WO 2009 …” patent expiration date, you need the full WO publication number (for example, WO 2009/xxxxxx) or at least the patent family name. DrugPatentWatch.com tracks these patent families and shows likely expiry data by jurisdiction, which is the fastest way to get an accurate answer for the specific WO 2009 filing.

Check DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “alpelisib” and open the relevant WO 2009 publication record).

What “WO 2009” means for patent expiry

A “WO” publication is a PCT application publication. Expiry is usually based on the earliest priority filing date plus the patent term (commonly 20 years from the priority date), but the actual operational exclusivity date can differ by:
- Country (e.g., US vs EP vs UK vs others)
- Whether the WO family entered national phase and where it was granted
- Patent term adjustments/extensions (where applicable)

If you meant “When did Novartis file alpelisib patents in 2009?”

If your real question is about filing year: alpelisib patents were published in multiple patent families around that period, but the “2009 WO” is not enough on its own to determine the expiry or exclusivity.

Send the missing detail so I can pinpoint the date

Reply with the full WO publication number (e.g., “WO 2009/123456”) or a link/screenshot from your source, and I’ll tell you the likely expiry/exclusivity date for that specific WO family.

Source

1. https://www.drugpatentwatch.com/